ELIMSA
LIVE

Serial Number

79312543

Owner

YYZ Pharmatech, Inc.

Attorney

Nicole K. McLaughlin

Filing Date

Feb 18, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ELIMSA Trademark

Serial Number: 79312543 • Registration: 6993636

ELIMSA is a trademark filed by YYZ Pharmatech, Inc. on February 18, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

YYZ Pharmatech, Inc.

2 Glenrose Ave. Lower Unit

Entity Type: 03

Trademark Details

Filing Date

February 18, 2021

Registration Date

March 7, 2023

Published for Opposition

December 20, 2022

Goods & Services

Laboratory and scientific equipment for diagnostic testing and medical treatment, namely, test tubes, microscope slides, incubators, laboratory robots, and chromatography supports being chromatography apparatus for laboratory use; Laboratory and scientific equipment for diagnostic testing and medical treatment, namely, diagnostic apparatus for the detection of pathogens for laboratory or research use; Laboratory and scientific equipment for diagnostic testing and medical treatment, namely, medical diagnostic simulators for use as teaching aids for detecting pathogens, DNA analysis, and chromatography; electrophoresis laboratory apparatus and instruments for extracting biomolecules within enzyme-linked immunosorbent assays, immunoblots, polymerase chain reactions (PCR), hybridization, binding assays, nucleic acids, DNA, RNA, proteins, and antigens, not for medical purposes; analytical apparatus in the nature of an automated slide stainer for use in medical laboratories; and replacement parts and fittings therefor

Diagnostic and test kits, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic and test kits, namely, drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids for the presence of protein, DNA, RNA, antibody, nanobody, aptamer, peptide, and biopolymer; Diagnostic and test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, infectious diseases, oncology being cancers, neurological diseases, immunological diseases, cardiovascular diseases, genetic diseases, environmental diseases, dietary diseases, and pathogens; diagnostic reagents for medicinal use; medical diagnostic reagents; Kits for testing of body fluids, namely, medical diagnostic reagents and assays for testing body fluids, tissues or cells for microorganisms; Kits for testing of body fluids, namely, medical diagnostic reagents and assays for testing of body fluids and tissue of cells for human health, capture and detection reagents for environmental use, human health, agriculture, food and nutrition; laboratory and scientific equipment for detection, quantification of analytes, biopolymers or germs, and diagnosis of virus, disease and pathogens, namely, diagnostic media for bacteriological cultures, medical diagnostic test media in the form of strip, threads, multi-well plates, microbeads, nanobeads, for measuring pathological condition, phenotypic condition, genotypic condition; and replacement parts and fittings therefor

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Oct 18, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 3, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 12, 2023 FICS
FINAL DISPOSITION PROCESSED
Jun 12, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 7, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 7, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 7, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Dec 21, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 20, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 20, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 30, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 30, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 30, 2022 NONP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 27, 2022 OPNX
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 14, 2022 CRFA
ASSIGNED TO LIE
Nov 14, 2022 ALIE
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 9, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 9, 2022 OPNR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 2, 2022 ERFR
EX PARTE APPEAL-INSTITUTED
Nov 2, 2022 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Nov 2, 2022 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Nov 2, 2022 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
May 3, 2022 GNFN
FINAL REFUSAL E-MAILED
May 3, 2022 GNFR
FINAL REFUSAL WRITTEN
May 3, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 4, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 4, 2022 TROA
ASSIGNED TO EXAMINER
Mar 9, 2022 DOCK
REFUSAL PROCESSED BY IB
Oct 30, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 5, 2021 RFCS
REFUSAL PROCESSED BY MPU
Oct 5, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 21, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 20, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 14, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 12, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 8, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 3, 2021 REPR